☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC reviews varenicline

The Midlands Therapeutic Review and Advisory Committee (MTRAC) has published a review of varenicline (Champix®) for smoking cessation.

Varenicline has been assessed as a Q3 drug, having a lower place in therapy and strong evidence. The reason given for the lower placing in therapy is the lack of comparative efficacy data versus nicotine replacement therapy. The overall advice is that varenicline is "suitable for prescribing in primary care for healthy adult smokers with no serious medical conditions (e.g. major depression, cardiovascular disease, uncontrolled hypertension)".

Action: As already discussed, nicotine replacement therapy remains the first line choice. Varenicline (and bupropion) are suitable alternatives where NRT treatment fails.

Share 'MTRAC reviews varenicline' on Email Share 'MTRAC reviews varenicline' on Delicious Share 'MTRAC reviews varenicline' on Digg Share 'MTRAC reviews varenicline' on Facebook Share 'MTRAC reviews varenicline' on reddit Share 'MTRAC reviews varenicline' on Twitter

atomic-wealth

No Comments to “MTRAC reviews varenicline”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

vipers